Potential efficacy of zonisamide in refractory juvenile myoclonic epilepsy: Retrospective evidence from an Irish compassionate-use case series

Irish Medical Journal

Volumn 100, Issue 4, 2007, Pages

  O'Rourke, Deirdre ^a   Delanty, Norman ^a   Doherty, Colin ^b   White, Maire ^b   Flynn, C ^b  

^a BEAUMONT HOSPITAL   (Ireland)

^b Beaumont Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; FELBAMATE; ZONISAMIDE; ISOXAZOLE DERIVATIVE;

ADULT; ANOREXIA; ANTICONVULSANT ACTIVITY; ANXIETY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; IRELAND; MALE; MYOCLONUS; MYOCLONUS EPILEPSY; PARESTHESIA; PROGNOSIS; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; WEIGHT REDUCTION; ADOLESCENT; EMPATHY; PATHOPHYSIOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTICONVULSANTS; EMPATHY; FEMALE; HUMANS; IRELAND; ISOXAZOLES; MYOCLONIC EPILEPSY, JUVENILE; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34249805093     PISSN: 03323102     EISSN: 03323102     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Renganathan R, Delanty N. Juvenile myoclonic epilepsy: under-appreciated and under-diagnosed. Postgrad Med J 2003;79:78-80.
2. Sullivan J, Dlugos D. Idiopathic generalized epilepsy. Curr Treat Options Neurol 2004;6:231-242.
3. Gelisse P, Genton P, Thomas P, Rey M, Samuelian JC, Dravet C. Clinical factors of drug resistance in juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 2001; 70:240-243.
4. Wheless JW, Sankar R. Treatment strategies for myoclonic seizures and epilepsy syndromes with myoclonic seizures. Epilepsia 2003;44 (suppl 11) 27-37.
5. Grunewald R. Levetiracetam in the treatment of idiopathic generalized epilepsies. Epilepsia 2005; 46 (suppl 9):154-160.
6. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for Revised Classification of Epilepsies and Epileptic Syndromes. Epilepsia 1989; 30:389-399
7. Carmondy J, Delanty N. Juvenile myoclonic epilepsy masquerading as ecstasy withdrawal. Ir Med J 2005; 98:281.
8. Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomised, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005; 46: 31-41.
9. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 1998; 20: 593-597
10. Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigineand zonisamide. Epilepsy Res 1998; 29: 147-154.
11. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugsII: Treatment of refractory epilepsy. Neurology 2004; 62: 1261-1273.
12. Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. J Child Neurol 2002;17: 87-96.
13. Yagi K. Overview of Japanese experience - controlled and uncontrolled trials. Seizure 2004;13(suppl 1): 11-15.
14. Kothare S, Valencia I, Khurana DS, Hardison H, Melvin JJ, Legido A. Efficacy and tolerability of zonisamide in uvenile myoclonic epilepsy. Epileptic Disord 2004; 6: 267-270.
15. Szaflarski JP. Effects of zonisamide on the electroencephalogram of a patient with juvenile myoclonic epilepsy. Epilepsy Behav; 2004;5:1024-1026.
16. Mullin P, Stern JM, Delgado-Escueta AV, Eliashiv D. Effectiveness of open-label zonisamide in juvenile myoclonic epilepsy. Epilepsia 2001; 42 (suppl 7) 184.
17. Biton V, Bebin ME. Multicenter, open-label assessment of the efficacy and safety of zonisamide as adjunctive therapy for primary generalized epilepsy. Epilepsia 2002; 43 (suppl 7) 190.
18. Faught E. Clinical trials for treatment of primary generalized epilepsies. Epilepsia 2003; 44 (suppl 7) 44-50